Malaria vaccine live unattenuated plus chloroquine - Sanaria

Drug Profile

Malaria vaccine live unattenuated plus chloroquine - Sanaria

Alternative Names: PfSPZ Challenge plus chloroquine; PfSPZ CVac; PfSPZ malaria vaccine live unattenuated plus chloroquine - Sanaria; Plasmodium falciparum sporozoite vaccine live unattenuated plus chloroquine - Sanaria

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanaria
  • Developer National Institute of Allergy and Infectious Diseases; Sanaria
  • Class Antimalarials; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Falciparum malaria

Most Recent Events

  • 19 Apr 2018 Sanaria plans a phase II trial for Falciparum malaria (prevention) in Indonesia , (NCT03503058)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Falciparum-malaria(Prevention) in Germany (IV, Injection)
  • 20 Feb 2017 Sanaria plans phase III trial for Falciparum malaria (Prevention) in Africa, Europe and the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top